Literature DB >> 6604071

Lymphocyte subsets in measles. Depressed helper/inducer subpopulation reversed by in vitro treatment with levamisole and ascorbic acid.

M I Joffe, N R Sukha, A R Rabson.   

Abstract

Lymphocyte subsets were assessed in patients with measles using the OKT range of monoclonal antibodies. A significant decrease in cells reacting with the OKT3 and OKT4 monoclonal antibodies was observed. When the tests were repeated 3 wk after the acute infection, significant recovery of these subsets was observed. The abnormality in lymphocyte subsets could be reproduced by treating normal lymphocytes with measles virus in vitro. When lymphocytes from patients with measles or when normal cells infected with measles virus in vitro were treated with either levamisole or L-ascorbic acid for 15 min and then retested with the OKT antisera, restoration of the previously depleted OKT3+ and OKT4+ cell population was observed. Ascorbic-acid treatment also, to a certain extent, reversed the inability of measles mononuclear cells to produce lymphocyte mitogenic factor (helper factor for B cells) after pokeweed mitogen activation. This abnormality, however, could not be reversed by in vitro treatment with levamisole. Measles patients treated with L-ascorbic acid demonstrated no accelerated recovery in either their lymphocyte subset profile or their ability to produce lymphocyte mitogenic factor. Although the cause of the depressed OKT3+ and OKT4+ lymphocyte subpopulations in patients with measles is not clear, the results suggest that the effect is not due to an aberration of protein synthesis, but rather to a blocking or steric change produced by the virus on the cell membrane. It is likely that both ascorbic acid and levamisole have the ability to reverse this effect by virtue of their antioxidant properties.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6604071      PMCID: PMC1129263          DOI: 10.1172/JCI111069

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  A monoclonal antibody with selective reactivity with functionally mature human thymocytes and all peripheral human T cells.

Authors:  E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

Review 2.  Levamisole in the modulation of the immune response: the current experimental and clinical state.

Authors:  J Symoens; M Rosenthal
Journal:  J Reticuloendothel Soc       Date:  1977-03

3.  Effects of levamisole and imidazole on lymphocyte proliferation and cyclic nucleotide levels.

Authors:  J W Hadden; R G Coffey; E M Hadden; E Lopez-Corrales; G H Sunshine
Journal:  Cell Immunol       Date:  1975-11       Impact factor: 4.868

4.  Inactivation of enteroviruses by ascorbic acid and sodium bisulfite.

Authors:  R J Salo; D O Cliver
Journal:  Appl Environ Microbiol       Date:  1978-07       Impact factor: 4.792

5.  Cell-mediated immunity during natural measles infection.

Authors:  H C Whittle; J Dossetor; A Oduloju; A D Bryceson; B M Greenwood
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

6.  Separation of functional subsets of human T cells by a monoclonal antibody.

Authors:  E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

7.  Levamisole increases activated T lymphocytes.

Authors:  M Rosenthal
Journal:  Lancet       Date:  1977-09-24       Impact factor: 79.321

8.  Human macrophage and lymphocyte responses to mitogen stimulation after exposure to influenza virus, ascorbic acid, and hyperthermia.

Authors:  J P Manzella; N J Roberts
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

9.  Dissociation of lymphokine production and blastogenesis in children with measles infections.

Authors:  M I Joffe; A R Rabson
Journal:  Clin Immunol Immunopathol       Date:  1978-07

10.  Immune responses during measles infection in immunosuppressed Rhesus monkeys.

Authors:  J T Hicks; J L Sullivan; P Albrecht
Journal:  J Immunol       Date:  1977-10       Impact factor: 5.422

View more
  8 in total

1.  Functional and phenotypic changes in circulating lymphocytes from hospitalized zambian children with measles.

Authors:  Judith J Ryon; William J Moss; Mwaka Monze; Diane E Griffin
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

2.  The inflammatory cytokines in measles: correlation between serum interferon-gamma levels and lymphocyte subpopulations.

Authors:  S Ohga; C Miyazaki; K Okada; K Akazawa; K Ueda
Journal:  Eur J Pediatr       Date:  1992-07       Impact factor: 3.183

Review 3.  Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19).

Authors:  Ehsaneh Khodadadi; Parham Maroufi; Ehsan Khodadadi; Isabella Esposito; Khudaverdi Ganbarov; Silvano Espsoito; Mehdi Yousefi; Elham Zeinalzadeh; Hossein Samadi Kafil
Journal:  Microb Pathog       Date:  2020-05-05       Impact factor: 3.738

4.  Potential interventions for novel coronavirus in China: A systematic review.

Authors:  Lei Zhang; Yunhui Liu
Journal:  J Med Virol       Date:  2020-03-03       Impact factor: 2.327

5.  Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial.

Authors:  Amirreza Roostaei Firozabad; Zohreh Akhoundi Meybodi; Seyed Ruhollah Mousavinasab; Adeleh Sahebnasagh; Mohsen Gholinataj Jelodar; Iman Karimzadeh; Solomon Habtemariam; Fatemeh Saghafi
Journal:  BMC Infect Dis       Date:  2021-03-24       Impact factor: 3.090

Review 6.  A Review on Measures to Rejuvenate Immune System: Natural Mode of Protection Against Coronavirus Infection.

Authors:  Md Aminul Islam; Md Atiqul Haque; Md Arifur Rahman; Foysal Hossen; Mahin Reza; Abanti Barua; Abdullah Al Marzan; Tuhin Das; Sumit Kumar Baral; Cheng He; Firoz Ahmed; Prosun Bhattacharya; Md Jakariya
Journal:  Front Immunol       Date:  2022-03-15       Impact factor: 7.561

Review 7.  COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future Management.

Authors:  Md Farhad Hossain; Sharifa Hasana; Abdullah Al Mamun; Md Sahab Uddin; Mir Imam Ibne Wahed; Sabarni Sarker; Tapan Behl; Irfan Ullah; Yesmin Begum; Israt Jahan Bulbul; Md Shah Amran; Md Habibur Rahman; May N Bin-Jumah; Saad Alkahtani; Shaker A Mousa; Lotfi Aleya; Mohamed M Abdel-Daim
Journal:  Front Pharmacol       Date:  2020-10-16       Impact factor: 5.810

Review 8.  Pharmacological treatments of COVID-19.

Authors:  Adeleh Sahebnasagh; Razieh Avan; Fatemeh Saghafi; Mojataba Mojtahedzadeh; Afsaneh Sadremomtaz; Omid Arasteh; Asal Tanzifi; Fatemeh Faramarzi; Reza Negarandeh; Mohammadreza Safdari; Masoud Khataminia; Hassan Rezai Ghaleno; Solomon Habtemariam; Amirhosein Khoshi
Journal:  Pharmacol Rep       Date:  2020-08-20       Impact factor: 3.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.